Eikon Therapeutics raised $350.7 million in a Series D funding round to support its growth initiatives.
Amount Raised
$351 Million
Round Type
Series D
MillbraeBiotechnologyHealth CareTherapeuticsInvestors
Description
Eikon Therapeutics successfully completed a Series D funding round, raising $350.7 million. The funds will be utilized to advance their innovative therapeutic programs.
Quick answer
Eikon Therapeutics raised $351 Million in a Series D round, dated February 26, 2025. Investors: Soros Capital, General Catalyst, Foresite Capital, Column Group, AME Cloud Ventures and Alexandria Venture Investments. Eikon Therapeutics is based in Millbrae, California, United States.
- How much did Eikon Therapeutics raise?
- Eikon Therapeutics raised $351 Million in a Series D round on February 26, 2025.
- Who invested in Eikon Therapeutics?
- Soros Capital, General Catalyst, Foresite Capital, Column Group, AME Cloud Ventures and Alexandria Venture Investments are named as investors in this round.
- What does Eikon Therapeutics do?
- Eikon Therapeutics is advancing breakthrough therapies through the purposeful integration of science and engineering.
- Where is Eikon Therapeutics based and how big is it?
- Eikon Therapeutics is based in Millbrae, California, United States. Fundz records about 390 employees.
- Who are the decision-makers at Eikon Therapeutics?
- Fundz holds 1 contact at Eikon Therapeutics, including the Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Eikon Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- OncoNano Medicine raised $13M on April 11, 2025.
- Decoy Therapeutics raised $1.2M (Seed) on April 11, 2025.
- Merida Therapeutics raised $121M (Series A) on April 8, 2025.
- Accure Therapeutics S.L raised $1.6M (Seed) on April 7, 2025.
- Apeximmune Therapeutics raised $21M (Series A) on April 1, 2025.
- Prazer Therapeutics raised $22M (Series B) on April 1, 2025.
Who to call at Eikon Therapeutics, and when
A new round usually means Eikon Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Eikon Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Eikon Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Eikon Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Eikon Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Eikon Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.